Publications

  1. Cote GM, Conley AP, Attia S, Van Tine BA, Seetharam M, Chen YL, Gafoor Z, Heery C, Pico-Navarro C, Adams T. A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. Cancer. 2024 Nov 15; 130 (22):3845-3854 Epub 2024 July 10
    View PubMed
  2. Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma. Clin Cancer Res. 2024 Oct 15; 30 (20):4584-4592
    View PubMed
  3. Seligson ND, Asmann YW, Almerey T, Zayas YC, Edgar MA, Attia S, Knutson KL, Bagaria SP. Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas. Surg Oncol. 2024 Oct; 56:102125 Epub 2024 Aug 26
    View PubMed
  4. Garg P, Ali M, Alomari M, Schoolmeester JK, Edgar M, Attia S, Landolfo K. Cardiac Benign Metastatic Leiomyoma. JACC CardioOncol. 2024 Aug; 6 (4):617-621 Epub 2024 May 14
    View PubMed
  5. Van Tine BA, Ingham MA, Attia S, Meyer CF, Baird JD, Brooks-Asplund E, D'Silva D, Kong R, Mwatha A, O'Keefe K, Weetall M, Spiegel R, Schwartz GK. Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. J Clin Oncol. 2024 Jul 10; 42 (20):2404-2414 Epub 2024 Apr 29
    View PubMed
  6. Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Navid F, Farma JM, Ferrari A, Fiore M, Gladdy RA, Gounder M, Haas RL, Husson O, Kurtz JE, Lazar AJ, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AW, Sparber-Sauer M, Strauss DC, Van der Graaf WTA, Vitellaro M, Weiss AR, Gronchi A, Desmoid Tumor Working Group. Current Management of Desmoid Tumors: A Review. JAMA Oncol. 2024 Jun 20 Epub 2024 June 20
    View PubMed
  7. D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13; 403 (10435):1460-1471 Epub 2024 Mar 27
    View PubMed
  8. Heinrich MC, Jones RL, George S, Gelderblom H, Schoffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30 (2):498-506 Epub 2024 Jan 05
    View PubMed
  9. Gao L, Kaushik D, Van Tine BA, Ingham MA, Attia S, Meyer CF, Schwartz GK, Maliakal P, Baird JD, Ma J, Barrett R, D'Silva D, O'Keefe K, Kong R. Pharmacokinetics of Dacarbazine and Unesbulin and CYP1A2-Mediated Drug Interactions in Patients With Leiomyosarcoma. Clin Transl Sci. 2023 Dec 21; 17 (2) [Epub ahead of print]
    View PubMed
  10. Attia S, Villalobos V, Hindi N, Wagner AJ, Chmielowski B, Oakley GJ 3rd, Peterson PM, Ceccarelli M, Jones RL, Dickson MA. Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers (Basel). 2023 Oct 6; 15 (19) Epub 2023 Oct 06
    View PubMed
  11. Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S, INTRIGUE investigators. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer. 2023 Oct; 192:113245 Epub 2023 July 20
    View PubMed
  12. Ingham M, Allred JB, Chen L, Das B, Kochupurakkal B, Gano K, George S, Attia S, Burgess MA, Seetharam M, Boikos SA, Bui N, Chen JL, Close JL, Cote GM, Thaker PH, Ivy SP, Bose S, D'Andrea A, Marino-Enriquez A, Shapiro GI, Schwartz GK. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol. 2023 Sep 1; 41 (25):4154-4163 Epub 2023 July 19
    View PubMed
  13. Heater NK, Okuno S, Robinson S, Attia S, Seetharam M, Siontis BL, Yoon J, Chawla S, Milhem MM, Monga V, Skubitz K, Charlson J, Hirbe AC, Weiss MC, Van Tine B, Agulnik M. The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma. J Clin Med. 2023 Mar 29; 12 (7)
    View PubMed
  14. Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 9; 388 (10):898-912
    View PubMed
  15. Hoppe BS, Petersen IA, Wilke BK, DeWees TA, Imai R, Hug EB, Fiore MR, Debus J, Fossati P, Yamada S, Orlandi E, Zhang Q, Bao C, Seidensaal K, May BC, Harrell AC, Houdek MT, Vallow LA, Rose PS, Haddock MG, Ashman JB, Goulding KA, Attia S, Krishnan S, Mahajan A, Foote RL, Laack NN, Keole SR, Beltran CJ, Welch EM, Karim M, Ahmed SK. Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design. Cancers (Basel). 2023 Mar 8; 15 (6) Epub 2023 Mar 08
    View PubMed
  16. Wilke BK, Garner HW, Bestic JM, Chase LA, Heckman MG, Schoch JJ, Attia S. A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes. Clin Cancer Res. 2023 Feb 1; 29 (3):541-547
    View PubMed
  17. Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 2023 Jan; 12 (2):1532-1539 Epub 2022 Aug 10
    View PubMed
  18. Isaza LF, Garner HW, Edgar MA, Attia S, Wilke BK. A case report of 2 distinct primary sarcomas arising in an extremity in rapid succession. Radiol Case Rep. 2023 Jan; 18 (1):70-74 Epub 2022 Oct 27
    View PubMed
  19. Schoffski P, George S, Heinrich MC, Zalcberg JR, Bauer S, Gelderblom H, Serrano C, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Becker C, Shi K, Meade J, Ruiz-Soto R, Blay JY, von Mehren M. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial. BMC Cancer. 2022 Dec 13; 22 (1):1302
    View PubMed
  20. Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schoffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Su Y, Meade J, Wang T, Sherman ML, Ruiz-Soto R, Heinrich MC. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Dec 1; 40 (34):3918-3928 Epub 2022 Aug 10
    View PubMed
  21. Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Groschel S, Hatcher H, Duffaud F, Herraez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Gotze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 Aug 1; 40 (22):2479-2490 Epub 2022 Apr 08
    View PubMed
  22. Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022 Jun 15; 13 (1):3406 Epub 2022 June 15
    View PubMed
  23. Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1; 8 (5):740-747
    View PubMed
  24. Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2022 Apr 20; 40 (12):1291-1300 Epub 2021 July 14
    View PubMed
  25. Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schoffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 Dec 1; 27 (23):6333-6342 Epub 2021 Sept 09
    View PubMed
  26. Zalcberg JR, Heinrich MC, George S, Bauer S, Schoffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 Nov; 26 (11):e2053-e2060 Epub 2021 Aug 16
    View PubMed
  27. Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, Attia S, Rademaker A, Zhang H, Abbinanti S, Cehic R, Monga V, Milhem M, Okuno S, Van Tine BA. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021 Sep; 154:201-208 Epub 2021 July 17
    View PubMed
  28. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 Aug; 125 (4):528-533 Epub 2021 May 28
    View PubMed
  29. Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17 (22):2923-2939 Epub 2021 Apr 15
    View PubMed
  30. Akinduro OO, Suarez-Meade P, Garcia D, Brown DA, Sarabia-Estrada R, Attia S, Gokaslan ZL, Quinones-Hinojosa A. Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy. Target Oncol. 2021 May; 16 (3):325-337 Epub 2021 Apr 24
    View PubMed
  31. Bojanini L, Attia S, Heagney H, Gonzalez-Estrada A. Long induction of tolerance to imatinib. BMJ Case Rep. 2020 Dec 13; 13 (12)
    View PubMed
  32. Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist. 2020 Nov; 25 (11):e1655-e1662 Epub 2020 Aug 20
    View PubMed
  33. Gounder M, Schoffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov; 21 (11):1423-1432 Epub 2020 Oct 06
    View PubMed
  34. Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020 Sep; 137:1-9 Epub 2020 July 23
    View PubMed
  35. Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, Van Tine BA, Oppelt P, Okuno S, Robinson S, O'Connor M, Seetharam M, Attia S, Charlson J, Agulnik M, Milhem M. A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. Cancers (Basel). 2020 Jul 11; 12 (7) Epub 2020 July 11
    View PubMed
  36. Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 Jul; 9 (13):4593-4602 Epub 2020 May 06
    View PubMed
  37. Jacob S, Carroll ND, El-Sayed Ahmed MM, Attia S, Jim Zhai Q, Bower SP, Makey IA. Thoracoabdominal resection of giant malignant esophageal solitary fibrous tumor. J Surg Case Rep. 2020 Jul; 2020 (7):rjaa152 Epub 2020 July 14
    View PubMed
  38. Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schoffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jul; 21 (7):923-934 Epub 2020 June 05
    View PubMed
  39. Younger E, Ballman K, Lu Y, Papai Z, Van Tine BA, Attia S, Schoffski P, Reinke D, Tap WD, Jones RL. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. J Geriatr Oncol. 2020 Apr; 11 (3):463-469 Epub 2019 May 22
    View PubMed
  40. Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 Mar 15; 26 (6):1258-1266 Epub 2020 Jan 03
    View PubMed
  41. Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, Breuing J, Cardona K, Casali PG, van F, Colombo C, Dei AP, Dileo P, Ferrari A, Fiore M, Frezza AM, Garcia J, Gladdy R, Gounder M, Gronchi A, Haas R, Hackett S, Haller F, Hohenberger P, Husson O, Jones RL, Judson I, Kasper B, Kawai A, Kogosov V, Lazar AJ, Maki R, Mathes T, Messiou C, Navid F, Nishida Y, Palassini E, Penel N, Pollock R, Pieper D, Portnoy M, Raut CP, Roets E, Sandrucci S, Sbaraglia M, Stacchiotti S, Thornton KA, van W, van K, van WJ, Villalobos, Wagner AJ, Wardelmann E, Wartenberg M, Watson S, Weiss A, Zafiropoulos N, Desmoid Tumor Working Group . The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer.. 2020; 127:96-107.
  42. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 Nov; 15 (11):e925-e933 Epub 2019 July 03
    View PubMed
  43. Jones RL, Chawla SP, Attia S, Schoffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 Jul 15; 125 (14):2445-2454 Epub 2019 Apr 29
    View PubMed
  44. Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1; 37 (16):1424-1431 Epub 2019 Apr 23
    View PubMed
  45. Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20; 379(25):2417-2428.
    View PubMed
  46. van Tine BA, Mohindra N, Milhem M, Attia S, Robinson SI, Rademaker A, Okuno SH, Agulnik M. A phase II study of pazopanib with oral topotecan in patients with metastatic osteosarcoma. Ann Oncol. 2018 Oct; 29 Suppl 8:viii579
    View PubMed
  47. Gounder M, Schoffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers ET, Italiano A, Gupta A, Agulnik M, Attia S, Jones RL, van Tine BA, Demetri GDD, Roche M, Sapir I, Daigle S, Clawson A, Stacchiotti S. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950). Ann Oncol. 2018 Oct; 29 Suppl 8:viii581-viii582
    View PubMed
  48. Agulnik M, van Tine BA, Attia S, Rademaker A, Milhem M, Okuno SH. Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma. Ann Oncol. 2018 Oct; 29 Suppl 8:viii592
    View PubMed
  49. Daigle S, Stacchiotti S, Schoffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers ET, Italiano A, Gupta A, Agulnik M, Attia S, Jones RL, van Tine BA, Demetri GDD, Clawson A, Roche M, Blakemore S, Gounder M. Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Ann Oncol. 2018 Oct; 29 Suppl 8:viii670
    View PubMed
  50. Stacchiotti S, Blay JY, Jones RL, Demetri GDD, Mir O, Italiano A, Thomas D, Chen TW, Schoffski P, Gil T, Jahan T, Cote G, Ratan R, Attia S, Roche M, Daigle S, Sapir I, Clawson A, Gounder M. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Ann Oncol. 2018 Oct; 29 Suppl 8:viii580
    View PubMed
  51. Agulnik M, Attia S. Growing Role of Regorafenib in the Treatment of Patients with Sarcoma. Target Oncol. 2018 Aug; 13 (4):417-422
    View PubMed
  52. Bagaria SP, Neville M, Gray RJ, Gabriel E, Ashman JB, Attia S, Wasif N. The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions. Sarcoma. 2018; 2018:3056562 Epub 2018 July 24
    View PubMed
  53. Bagaria SP, Chang YH, Gray RJ, Ashman JB, Attia S, Wasif N. Improving Long-Term Outcomes for Patients with Extra-Abdominal Soft Tissue Sarcoma Regionalization to High-Volume Centers, Improved Compliance with Guidelines or Both? Sarcoma. 2018; 2018:8141056 Epub 2018 Apr 03
    View PubMed
  54. Bagaria SP, Gatalica Z, Maney T, Serie D, Parasramka M, Attia S, Krishna M, Joseph RW. Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. Front Oncol. 2018; 8:71 Epub 2018 Mar 22
    View PubMed
  55. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov; 18 (11):1493-1501 Epub 2017 Oct 04
    View PubMed
  56. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schoffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug; 18 (8):1089-1103 Epub 2017 June 23
    View PubMed
  57. Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW. Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. Rare Tumors. 2017 Jul 3; 9 (2):6834 Epub 2017 Sept 15
    View PubMed
  58. Jagadesh N, Miller DH, Schenk W, Attia S, Sherman CE, Cortese C, May BC, Miller RC. Recurrent myxoinflammatory fibroblastic sarcoma: a case report. Clin Case Rep. 2017 Jun; 5 (6):871-875 Epub 2017 Apr 20
    View PubMed
  59. Garner HW, Bestic JM, Peterson JJ, Attia S, Wessell DE. Preoperative radioactive seed localization of nonpalpable soft tissue masses: an established localization technique with a new application. Skeletal Radiol. 2017 Feb; 46 (2):209-216 Epub 2016 Nov 24
    View PubMed
  60. Kaleem TA, Schild MH, Miller D, Jha A, Cortese C, Attia S, Miller RC. Langerhan's Cell Sarcoma: Two Case Reports. Rare Tumors. 2016 Mar 21; 8 (1):6140 Epub 2016 Apr 06
    View PubMed
  61. Kaleem TA, Schild MH, Miller D, Jha A, Cortese C, Attia S, Miller RC. Langerhan’s cell sarcoma: Two case reports Rare Tumors. 2016; 8: (1)17-9.
  62. Brett CL, Miller DH, Jiang L, Wolfsen HC, Attia S, Hintenlang L, Jagadesh N, Miller RC. Dedifferentiated liposarcoma of the esophagus: A case report and selected review of the literature Rare Tumors. 2016; 8: (4)201-2.
  63. Bagaria SP, Wagie AE, Gray RJ, Pockaj BA, Attia S, Habermann EB, Wasif N. Validation of a Soft Tissue Sarcoma Nomogram Using a National Cancer Registry. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S398-403 Epub 2015 Sept 09
    View PubMed
  64. Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC. Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass. J Clin Oncol. 2015 Jun 10; 33 (17):e74-6 Epub 2014 Mar 24
    View PubMed
  65. Sood N, Swaika A, Hanooshi B, Waldorf J, Peterson J, Wu K, Attia S, Dinh TA. High Grade Leiomyosarcoma Mimicking a Recurrent Angiomyxoma in the Perineum. Rare Tumors. 2015 May 5; 7 (2):5875 Epub 2015 May 19
    View PubMed
  66. Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Bagaria SP, Jones RL, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors. 2015 May 5; 7 (2):5992 Epub 2015 May 21
    View PubMed
  67. Jaime Davila, Yan Asmann, Jason Starr, Steven Attia, Chen Wang, Ryan Knudson, Brian Necela, Vivekananda Sarangi, Gavin R Oliver, Zhifu Sun, Raymond Moore, Xue Wang, John Casler, David Menke, Richard Joseph, John A Copland, Alexander Parker, Jean Pierre, Kocher, Aubrey Thompson, Robert C Smallridge. Extensive genomic profiling of a rare extranodal-follicular dendritic cell sarcoma reveals mutations in drug targetable genes, extensive copy number changes and novel fusions. JAMA. May 2015 (submitted).
  68. Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG. Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma. Rare Tumors. 2015; 7(2):86-8.
  69. Noriega-Iriondo MF, Colon-Otero G, Kipp BR, Copland JA, Ferber MJ, Marlow LA, Roberts ME, Robertson MW, Dinh TA, Attia S, Geiger XJ, Riegert-Johnson DL. High-grade endometrial stromal sarcoma as the initial presentation of an adult patient with Peutz-Jeghers Syndrome: a case report. Hered Cancer Clin Pract. 2015; 13 (1):6 Epub 2015 Jan 23
    View PubMed
  70. Conley AP, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. J Clin Oncol. 2014 Nov 10; 32 (32):e107-10 Epub 2014 Feb 18
    View PubMed
  71. Carey K, Bestic J, Attia S, Cortese C, Jain M. Diffuse skeletal muscle metastases from sacral chordoma. Skeletal Radiol. 2014 Jul; 43 (7):985-9 Epub 2014 Jan 10
    View PubMed
  72. Islam R, Rafiullah A, Thogarucheeti B, Hague N, Attia S. A case of biphasic sarcoma with lung and breast metastasis responding to pazopanib. Journal of Clinical Oncology and Research. 2014 May 5; 2(5):1037.
  73. Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec; 31(6):1539-46. Epub 2013 Oct 10.
    View PubMed
  74. Buehler D, Rice SR, Moody JS, Rush P, Hafez GR, Attia S, Longley BJ, Kozak KR. Angiosarcoma Outcomes and Prognostic Factors: A 25-Year Single Institution Experience. Am J Clin Oncol. 2013 Feb 20.
    View PubMed
  75. Cornett D, Benson M, Attia S, Weiss J, Gopal D. Metastatic Kaposi's Sarcoma with Perirectal Involvement Diagnosed with Endoscopic Ultrasound-Guided EchoBrush Cytology Sampling. Case Rep Gastroenterol. 2011 May; 5(2):416-21. Epub 2011 Jul 22.
    View PubMed
  76. McHaffie DR, Kozak KR, Warner TF, Cho CS, Heiner JP, Attia S. Stewart-Treves syndrome of the lower extremity. J Clin Oncol. 2010 Jul 20; 28(21):e351-2. Epub 2010 Apr 05.
    View PubMed
  77. Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR. AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol. 2010 Jun 1; 28(16):e250-1. Epub 2010 May 03.
    View PubMed
  78. Weiss JM, Attia S, Bailey HH, Weber S, Hu J, Reichelderfer M, Gopal DV. Metastatic soft tissue sarcoma diagnosed by small bowel video capsule endoscopy. J Clin Oncol. 2010 May 20; 28(15):e233-5. Epub 2010 Apr 05.
    View PubMed
  79. Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009 Jun; 64(1):79-86. Epub 2008 Oct 22.
    View PubMed
  80. Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun; 64(1):45-51. Epub 2008 Oct 08.
    View PubMed
  81. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH. Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol. 2008 Sep; 3(9):1018-25.
    View PubMed
  82. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs. 2008 Aug; 26(4):369-79. Epub 2008 Feb 16.
    View PubMed
  83. Shaw A, Attia S, Bushman W. Prostate stromal and urogenital sinus mesenchymal cell lines for investigations of stromal-epithelial interactions. Differentiation. 2008 Jul; 76(6):599-605. Epub 2008 May 07.
    View PubMed
  84. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008 Jun; 62(1):149-57. Epub 2007 Sep 21.
    View PubMed
  85. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
    View PubMed
  86. Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol. 2008 Jan; 6(1):44-54.
    View PubMed
  87. Attia S, Wilding G. Novel antioxidant technology for prostate cancer chemoprevention and treatment. Expert Opin Ther Pat. 2006 Sep; 16(9):1255-67.
    View PubMed
  88. Ajmani PS, Attia S, Osifchin M, Regen S, Hughes JA. A spermine-deoxycholic acid conjugate based lipid as a transfecting agent. Pharmazie. 1999 Mar; 54(3):191-4.
    View PubMed
  89. Attia SA, Shepherd VE, Rosenblatt MN, Davidson MK, Hughes JA. Interaction of oligodeoxynucleotides with mycobacteria: implications for new therapeutic strategies. Antisense Nucleic Acid Drug Dev. 1998 Jun; 8(3):207-14.
    View PubMed
  90. Brazeau GA, Attia S, Poxon S, Hughes JA. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery. Pharm Res. 1998 May; 15(5):680-4.
    View PubMed